Organization
INSERM U1037
1 abstract
Abstract
Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI).Org: Université de Poitiers et Centre Hospitalier Universitaire de Poitiers, INSERM U1313 and CIC 1082, Poitiers, France, Hôpital Haut Leveque, University Hospital, Pessac, France, ECSTRA, Centre de Recherche en Epidémiologie et Statistiques, INSERM UMR 1153, Paris, France, Lille University Hospital, Lille, France, CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d’Hématologie, Toulouse, France,